Clinical Trial Update: Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating apatinib combined with XELOX as neoadjuvant therapy for locally advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Chemotherapy Effect, Chemotherapeutic Toxicity | Phase 2 | Status: UNKNOWN